In postoperative patients with breast cancer, the combination of an anthracycline and cyclophosphamide (AC) followed by a taxane is a standard regimen. In the current study, the authors examined whether AC could be safely omitted, and compared the effectiveness of paclitaxel versus docetaxel. . Neutropenia, nausea, and vomiting were found to occur more often in the AC-containing arms, whereas the incidence of edema was greater in the docetaxel-containing treatment arms. CONCLUSIONS: Noninferiority in DFS was not demonstrated between the AC-containing and AC-free regimens. Compared with a similar regimen of paclitaxel, docetaxel appeared to increase the DFS. Cancer 2017;123:759-68.
INTRODUCTION
The combination of an anthracycline and a taxane (4 cycles of doxorubicin plus cyclophosphamide [AC] followed by 4 cycles of paclitaxel) is the standard chemotherapeutic regimen for patients with lymph node-positive breast cancer. [1] [2] [3] [4] Unfortunately, rare but potentially fatal complications (cardiomyopathy and secondary leukemia) are associated with AC, for which no preventive regimens free of anthracyclines and cyclophosphamide offer safer clinical alternatives. [5] [6] [7] To our knowledge, it also is not known whether paclitaxel or docetaxel is more effective for patients with breast cancer. In metastatic settings, docetaxel (at a dose of 100 mg/m 2 ) has been compared with paclitaxel (at a dose of 175 mg/m 2 ), in which both were administered every 21 days. 8 The Eastern Cooperative Oncology Group 1199 trial compared the efficacy of paclitaxel and docetaxel in triweekly and weekly regimens in adjuvant settings. 9 In the current study, we examined the clinical benefit of AC followed by a taxane regimen compared with an AC-free regimen for patients with breast cancer in adjuvant settings. We also compared the clinical difference between the 2 taxanes given every 3 weeks.
MATERIALS AND METHODS

Participants
Eligible participants were defined as female patients with postoperative breast cancer who were aged 18 to 70 years with histologically confirmed invasive disease and positive axillary lymph nodes diagnosed after sentinel lymph node biopsy or dissection; any estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status; an Eastern Cooperative Oncology Group performance status of 0 to 1; and adequate hematologic, hepatic, and renal function. In terms of hormone status, patients who were positive for ER and/ or PgR were ineligible initially. However, such eligibility was amended on June 14, 2003 to permit the enrollment of patients with any ER-positive and PgR-positive disease following data from the Cancer and Leukemia Group B (CALGB) 9344 trial 1 showing that the survival benefits associated with taxanes are not only observed in patients with receptor-negative disease.
Exclusion criteria included a history of myocardial infarction, congestive heart failure, or significant ischemic heart disease. Patients were required to initiate the protocol-designated treatment within 84 days from the final surgical procedure.
The protocol was approved independently by the Institutional Review Board (IRB) at each institution/hospital before the initiation of patient enrollment. The first approval was given by the IRB of Aichi Prefectural Hospital (also known as Aichi Cancer Center Aichi Hospital) on September 4, 2001 , and also by the IRB of the principal investigator's hospital (the National Cancer Center Hospital) on January 24, 2002. The protocol is available at http://www.csp.or.jp/cspor/en/n-sas_bc02. html. The study was registered to the Japanese University Hospital Medical Information Network (UMIN; clinical trial registration UMIN-CTR C000000055). The UMIN Clinical Trial Registry satisfies the criteria of the International Committee of Medical Journal Editors. All patients provided written informed consent before participating in the current study.
Study Design and Procedures
The current trial examined 2 clinical hypotheses: 1) 8 cycles of a taxane are noninferior to 4 cycles of AC followed by 4 cycles of a taxane; and 2) one of the taxanes (paclitaxel or docetaxel) is superior or equivalent to the other.
We compared an AC-containing versus an AC-free regimen as well as 2 taxanes (paclitaxel vs docetaxel). Thus, we adopted a 2 3 2 factorial design with the following 4 treatment arms: 1) 4 cycles of doxorubicin at a dose of 60 mg/m 2 and cyclophosphamide at a dose of 600 mg/ m 2 (AC) followed by 4 cycles of paclitaxel at a dose of 175 mg/m 2 (ACpT; control arm); 2) AC followed by 4 cycles of docetaxel at a dose of 75 mg/m 2 (ACdT); 3) 8 cycles of paclitaxel at a dose of 175 mg/m 2 (PTx); and 4) 8 cycles of docetaxel at a dose of 75 mg/m 2 (DTx). Treatments in all arms were provided every 3 weeks (Fig. 1) . Prophylactic use of granulocyte colony-stimulating factor was prohibited during the study period.
Patients were randomly assigned at the Comprehensive Support Project for Oncological Research (CSPOR) Data Center to 1 of 4 treatment arms ( Fig. 2) with equal probability using the method of minimization over 6 stratification factors. These factors included tumor size (<3.0 cm vs 3.0 cm), hormone receptor status (both ER negative and PgR negative or others), HER2 status (21, 31, or others), surgical procedure (breast-conserving surgery or mastectomy), number of positive axillary lymph nodes (1-3, 4-9, or 10), and institution. Data from HER2 fluorescence in situ hybridization assays were not available. Because the current study was an open-label trial, no masking protocols were required. The randomization algorithm was designed and executed by a biostatistician (YO).
In all treatment arms, patients whose tumors were positive for ER, PgR, or both received tamoxifen or an aromatase inhibitor for 5 years after the completion of chemotherapy. Patients with HER2-positive breast cancer were not treated with trastuzumab unless distant Original Article metastases were detected because adjuvant therapy with trastuzumab was not approved in Japan until February 2008, which was 22 months after enrollment was closed for the current trial.
Endpoints
The planned study period included 3 years of patient enrollment and at least 5 years with a maximum of 10 years of follow-up for each patient until the occurrence of events. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS), adverse events, and health-related quality of life. DFS was defined as the period from randomization until the date of the first event, including local/regional disease recurrence, distant metastasis, invasive contralateral breast cancer, and death from any cause. OS was defined as the period from randomization until the date of death, regardless of cause. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0). All eligible patients, patients with disease recurrence, and records of patients who died were reviewed by the central committee for safety and efficacy.
Statistical Methods
The current trial was designed to confirm the noninferiority between AC-containing (ACpT and ACdT) and ACfree (PTx and DTx) regimens with regard to DFS and to guarantee sufficient statistical power. The secondary hypothesis, the comparison of 2 taxanes (ACpT and PTx vs ACdT and DTx), was the exploratory issue in this trial and requires confirmation via subsequent meta-analyses of other studies. We used the estimated hazard ratio (HR) and/or its confidence interval (CI) for the DFS analysis due to the respective survival data. The HRs of the regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) compared with nontreatment, AC compared with CMF, and AC plus a taxane compared with AC from the Early Breast Cancer Trialists' Collaborative Group and Cancer and Leukemia Group B (CALGB) 9344 trials were 0.76, 0.88, and 0.78 to 0.86, respectively. The threshold for noninferiority hypothesis verification (D) sets use of a taxane alone as at least superior to CMF as the minimum condition guaranteeing efficacy. Thus, the upper limit of the HR for the use of a taxane alone compared with AC plus a taxane is set at 1.321 (1/0.88 3 0.86). If D 5 1.321, the true HRs are 1.0 (taxane alone is equivalent) and 1.06 (taxane alone is slightly inferior), with an a of .05 (1-sided, 90% confidence interval [CI]), b 5 .20), and the number of events required for validation based on a normal approximation of the log HR estimate is 320 and 480, respectively, in the 2 groups. To observe 320 or 480 events, 800 to 1200 patients would be required for this study, assuming a minimum follow-up period of 5 years. Trial outcomes were analyzed by a biostatistician according to the initial plan.
Interim analyses were planned so that when the expected number of events was reached, the trial would be stopped and the null hypothesis would be rejected if the upper limit of the 99.0% CI was 1.321 for noninferiority or if the upper limit of the 99.5% CI for either taxane did not exceed 1.0 for superiority.
Cumulative survival curves for DFS and OS were estimated using the Kaplan-Meier method. HRs were estimated using the Cox regression model. Subgroup analyses were preplanned to compare each DFS and/or OS in the 4 trial groups in terms of ER-and HER2 status, respectively. All statistical analyses were conducted using SAS statistical software (version 9.2; SAS Institute Inc, Cary, NC).
RESULTS
Between December 2001 and April 2006, a total of 1060 patients were enrolled at 84 participating institutions in Japan. Figure 2 shows the trial profile. A total of 904 patients (85.2%) completed the protocol treatment. Table 1 provides the baseline characteristics of the 1049 patients whose data were included in the intention-totreat analysis.
The interim analysis was conducted on June 15, 2008, when the number of the latest group of patients reached 75% but did not meet the criteria to stop the trial. For the final analysis, noninferiority required the upper limit of the 90.3% CI to be 1.321, and superiority required a 95.2% CI that did not exceed 1.0.
As of December 2013, the median follow-up was 84.5 months. There were 192 cases of disease recurrence among patients in the AC-containing treatment arms and 219 among those in the AC-free treatment arms. For the results of DFS analysis, the HR in the AC-free treatment arms and the AC-containing treatment arms was 1.19 (90.3% CI, 1.012-1.405), and did not satisfy the initial setting for noninferiority (P noninferiority 5 .30) (Fig. 3A) . Disease recurrence in the docetaxel-containing treatment arms (ACdT and DTx) and paclitaxel-containing treatment arms (ACpT and PTx) were 178 and 233, respectively (Fig. 3B) . The median DFS in the ACpT (reference) treatment arm was 84.4 months (95% CI, 79.3-93.1 months). Other median DFS values were 85.7 months (95% CI, 82.6-95.5 months) in the ACdT arm, 87.9 months (95% CI, 84.1-94.8 months) in the DTx arm, and 78.0 months (95% CI, 60.5-84.1 months) in the PTx arm (Fig. 3C) .
Noninferiority between the AC-containing and ACfree treatment arms was demonstrated in terms of OS (Fig. 4A ). There was a significant difference in OS observed between the docetaxel-containing treatment arms Abbreviations: ACdT, 4 cycles of the combination of doxorubicin plus cyclophosphamide followed by 4 cycles of docetaxel; ACpT, 4 cycles of the combination of doxorubicin plus cyclophosphamide followed by 4 cycles of paclitaxel; DTx, docetaxel alone; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor; PTx, paclitaxel alone; SD, standard deviation. a Modified (muscle-preserving) radical mastectomy.
and the paclitaxel-containing treatment arms (Fig. 4B) . In the subgroup analysis, there was a stronger treatment effect for ACpT compared with PTx for patients with HER2-positive disease (HR, 1.85; 95% CI, 1.15-2.98) due to hormone receptors and/or HER2 status (Fig. 5) .
The most frequent grade 3 to 4 adverse event was neutropenia, which occurred more frequently in the ACcontaining treatment arms: 17.2% in the ACpT treatment arm and 19.5% in the ACdT treatment arm versus 1.9% in the PTx treatment arm and 6.9% in the DTx treatment arm ( Table 2 ). The incidence of febrile neutropenia also was found to be higher in the AC-containing treatment arms: 5.7% in the ACpT treatment arm and 11.1% in the ACdT treatment arm versus 0.4% in the PTx treatment arm and 8.1% in the DTx treatment arm.
Gastrointestinal adverse events were more frequently observed among patients in the AC-containing treatment arms than those in the AC-free treatment arms. Although edema was nearly unnoticeable in patients in the ACpT, ACdT, and PTx treatment arms, approximately 12.6% of patients in the DTx treatment arm reported this event.
Neuropathy was reported in all treatment arms; however, sensory neuropathy was infrequently observed in patients randomized to the ACdT treatment arm. Joint pain and muscle pain were common in all 3 treatment arms except the DTx arm.
DISCUSSION
To compare the clinical difference between AC-taxane and AC-free regimens and/or 2 taxanes, this randomized trial adopted a 2 3 2 factorial design of postoperative chemotherapy in patients with lymph node-positive breast cancer.
The current study could not demonstrate noninferiority between AC followed by a taxane and an AC-free regimen in terms of DFS. This may be a function of the PTx regimen (175 mg/m 2 every 3 weeks for 8 cycles) having resulted in the worst HR and median survival noted among the 4 regimens tested. Outcomes were better with the ACpT regimen compared with the PTx regimen, possibly because of an additive effect. Conversely, docetaxel alone (at a dose of 75 mg/m 2 every 3 weeks for 8 cycles) yielded the best outcome in terms of median survival and HR compared with the standard ACpT treatment arm. Thus, noninferiority could not be demonstrated when the 2 taxanes were analyzed jointly. The findings of the current study suggest that the combination of AC and a taxane cannot be replaced by taxane alone.
In terms of our second clinical question, the results of the current study did not demonstrate the equivalence or superiority of the 2 taxanes with regard to DFS and OS. The DTx and ACdT treatment arms proved superior to the standard ACpT treatment arm. This previously was demonstrated in a phase 3 study by Jones et al in which docetaxel (at a dose of 100 mg /m 2 every 3 weeks) was found to be superior to paclitaxel (at a dose of 175 mg/m 2 every 3 weeks) in terms of median survival and time to disease progression among patients with metastatic breast cancer. 8 At least in the current phase 3 study, the docetaxel-containing treatment arms appeared to be superior to the paclitaxel-containing treatment arms when administered every 3 weeks in an adjuvant regimen for patients with lymph node-positive breast cancer.
However, the dosing schedule between the 2 taxanes is at issue. Sparano et al compared the 2 taxanes with weekly and triweekly adjuvant treatment for breast cancer. Weekly paclitaxel proved superior over a triweekly dosing schedule. 9 This finding was corroborated in a randomized phase 3 trial by Seidman et al. 10 Schedule dependency (weekly dose-dense paclitaxel plus carboplatin every 3 weeks) of paclitaxel also was observed in patients with ovarian cancer. 11 Thus, paclitaxel appears to be more effective when administered weekly and docetaxel appears to be more effective when administered in a triweekly regimen. 8, 9 Triweekly administration of DTx would be a viable alternative to standard ACpT in the current study. However, we were unable to investigate the possibility of weekly administration with paclitaxel. This is a possible limitation to the current study.
It was not a standard clinical practice in the early 2000s, when this trial was designed, to select specific chemotherapeutic regimens for different biological subgroups of patients with breast cancer. An exploratory subset analysis demonstrated that the PTx regimen was notably inferior to the ACpT regimen in patients with HER2 overexpression. Similarly, HER2 positivity in breast cancer cells has since been associated with clinical responsiveness to anthracycline-containing chemotherapy 12 ; however, to the best of our knowledge, the precise biological mechanism of this observation remains unknown.
The incidence of neutropenic fever and gastrointestinal toxicity, such as nausea, vomiting, and mucositis, associated with docetaxel is notably low and acceptable. Peripheral edema was observed in 13% of patients in the DTx treatment arm, but this complication is manageable in the majority of patients with the use of corticosteroids and diuretics. 13 Although chemotherapy-induced peripheral neuropathy has been reported after treatment with taxanes, a patient-reported health-related quality of life assessment found that peripheral neuropathy after treatment with taxane alone was tolerable. 14 We conclude that AC cannot be omitted from the chemotherapeutic regimen for patients with lymph nodepositive breast cancer and that when docetaxel and paclitaxel are administered in a triweekly schedule, docetaxel results in better DFS. These results suggest that 8 cycles of triweekly administered docetaxel may offer some benefit for patients with lymph node-positive breast cancer. Further confirmatory trials are warranted to determine which subset of patients will benefit the most.
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